# US dermatologists put safety first (40.9%) and patient cost last (2.4%) when choosing a systemic therapy, yet 46.9% say coverage or cost overrode that choice in about half or more of their starts

*How do US dermatologists weigh cost, coverage and safety when starting a systemic therapy?*

Asked which one factor carries the most weight when starting a patient on a systemic therapy, 40.9% of US dermatologists name safety and 33.1% efficacy, with insurance coverage at 18.9% and the patient's out-of-pocket cost at 2.4% (n=127, September 2026), yet 46.9% say coverage or cost put a patient on something other than their clinical first choice in about half or more of their starts over the last year, and a $75 monthly out-of-pocket difference cuts the share who would simply prescribe their preferred agent from 69.3% to 12.6%.

- **Who was asked:** US dermatologists, 127 clones, US
- **When:** fielded 2026-09-14
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** The obvious question, "what matters most to you when prescribing a systemic?", gets safety and efficacy and stops there. Instead the single-factor forced choice was paired with two behavioral questions (whether the last start was the clinical first choice, and how often over a year coverage or cost changed the agent), the same preferred-agent-versus-older-agent scenario was restated in full three times at no extra cost, $75 and $300 a month so that cost is a slope rather than a rank, a boxed-warning scenario was run at two rates to test whether the number or the label carries the weight, and the panel was asked which one thing would move a new agent to first line, so the answer names the lever as well as the wall.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-09-14 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice

## What the panel said

1. **40.9%** Asked which one factor carries the most weight when they choose a systemic agent for moderate-to-severe inflammatory skin disease, 40.9% of US dermatologists name safety and the side-effect profile, 33.1% efficacy in trial data and their own experience, 18.9% whether the patient's insurance will cover it without a fight, 2.4% what the patient asks for and 2.4% what the patient will pay out of pocket; ease of administration (1.6%) and speed of onset (0.8%) trail. — base 127 (https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice#f1)
2. **46.9%** Over the last 12 months, insurance coverage or patient cost led 46.9% to start a systemic agent that was not their clinical first choice in about half of their starts or more (39.1% often, 7.8% almost always) and 43% in roughly one start in five; 10.2% say one or two patients or never. For their most recent start, 43% say the agent was not their clinical first choice, 39.1% because it was denied or not covered. — base 128, caveat (https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice#f2)
3. **12.6%** A $75 monthly out-of-pocket difference moves the decision out of the dermatologist's hands. With a preferred newer agent and an adequate older one both covered and no cost difference, 69.3% prescribe the preferred agent outright and 30.7% explain the difference and let the patient decide; at $75 more a month 12.6% still prescribe it outright and 87.4% hand the choice to the patient; at $300 more, 1.6% and 97.6%. Not one chose the older agent outright at any level. — base 127, contrast (https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice#f3)
4. **39.4%** Asked which one thing would most increase their willingness to prescribe a new systemic agent first-line, 39.4% say formulary coverage without step-therapy requirements, 33.1% five years of real-world safety data and 22.8% a head-to-head superiority trial; a near-zero co-pay program (1.6%), colleagues' experience (1.6%), a prior-authorization support service (0.8%) and oral dosing (0.8%) barely register. Formulary coverage is picked by 55.6% of those whose last start was overridden (n=54). — base 127, contrast (https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice#f4)

Chart — Asked which one factor carries the most weight when they choose a systemic agent for moderate-to-severe inflammatory skin disease, 40.9% of US dermatologists name safety and the side-effect profile, 33.1% efficacy in trial data and their own experience, 18.9% whether the patient's insurance will cover it without a fight, 2.4% what the patient asks for and 2.4% what the patient will pay out of pocket; ease of administration (1.6%) and speed of onset (0.8%) trail.:

- Safety and the side-effect profile: 40.9%
- Efficacy: 33.1%
- Whether insurance will cover it without a fight: 18.9%
- What the patient asks for: 2.4%
- What the patient will pay out of pocket: 2.4%
- Ease of administration and monitoring: 1.6%
- Speed of onset: 0.8%

## What is the first thing to take from this?

US dermatologists do not rank cost when they describe how they choose a systemic therapy, and then cost changes the answer anyway. Asked which one factor carries the most weight, 40.9% name safety and the side-effect profile, 33.1% efficacy and 18.9% whether the patient's insurance will cover the agent without a fight; the patient's out-of-pocket cost is named by 2.4%, three dermatologists in 127 (n=127). Asked how often coverage or cost led them to start something other than their clinical first choice over the last 12 months, 46.9% say about half of their starts or more and 89.8% say at least roughly one in five (n=128). For their most recent start, 43.0% say the agent was not the one they would have chosen on clinical grounds, and for 39.1% that was because the first choice was denied or not covered (n=128).

The same panel puts cost at 8 or more on a 0 to 10 scale for how much a patient's likely out-of-pocket cost changes which agent they prescribe: 82.7% score it 8, 9 or 10 (n=127). Cost is not what dermatologists weigh first. It is what moves the prescription.

## Where does the answer change, and for whom?

By practice setting, the override is heaviest at academic medical centers: 68.4% of academic dermatologists say coverage or cost changed the agent in about half of their starts or more (n=38), against 39.5% in solo and small practices (n=38) and 34.2% in large group practices (n=38). Academic dermatologists are also the most likely to say their last start was not their clinical first choice, 52.6% (n=38), and the most likely to name coverage as the factor with the most weight, 23.7% against 7.9% in large groups (n=38 each). Solo and small practices are the one setting where efficacy edges safety as the top factor, 14 to 13 of 38.

What a dermatologist weighs first predicts how they behave when a price appears. With the preferred newer agent covered but $75 a month more out of pocket, 26.2% of efficacy-first dermatologists still prescribe it outright (n=42) against 7.7% of safety-first dermatologists (n=52); the rest of both groups explain the difference and let the patient decide.

> **Coverage is named by the people it has already beaten**
>
> Among dermatologists whose last start was not their clinical first choice, 16 of 54 name coverage as the factor with the most weight; among those whose last start went as planned, 8 of 73 do.

## What happens when access gets in the way, and how much risk is tolerated?

When coverage or cost blocks the preferred agent, the panel splits four ways: 33.1% switch agent, 30.7% appeal, 17.3% turn to a patient assistance program and 16.5% go through step therapy (n=127). Delay is tolerated up to a point. Facing a one-week prior authorization, 85.0% are very likely to stay with their preferred therapy (n=127); at three weeks that falls to 23.0%, with 48.4% saying it depends (n=126); facing step therapy that requires a lower-cost systemic first, 36.2% are very unlikely to stay with the therapy they wanted (n=127). The barriers named most often are step therapy, 57.5%, and prior authorization, 55.9%, ahead of high patient cost at 41.7% (multi-select, n=127).

Safety works differently from cost: it is a label, not a slope. Offered a new agent with clearly better efficacy in a head-to-head trial but a boxed warning for a rare serious event, 89.7% would use it only after their current first choice had failed when the risk was put at about 1 in 1,000 patients a year (n=126), and 89.0% when it was put at about 1 in 10,000 (n=127). The number barely moved anyone; 115 of 126 gave the same answer at both rates. Biosimilars sit under the same payer logic: 95.3% use one only when the payer requires it (n=127).

## What would a market access or brand lead do with this?

1. Our reading: formulary coverage without step therapy is the lever, not a message. It is the single thing most likely to move a new agent to first line for 39.4% of the panel (n=127) and for 55.6% of those whose last start was just overridden (n=54).
2. Our reading: a co-pay program is not heard as access (1.6% pick it as the thing that would most increase first-line use, n=127), yet a $75 monthly gap is what hands the decision to the patient. Its job is to keep the out-of-pocket difference at zero, quietly, rather than to be the headline.
3. Our reading: the evidence that moves a dermatologist depends on what they weigh first. Five years of real-world safety data is the answer for 61.5% of the safety-first 40.9% (n=52); a head-to-head superiority trial is the answer for 42.9% of the efficacy-first 33.1% (n=42). One launch story will not serve both.
4. Our reading: a boxed warning is read as a second-line label whatever the rate on it. If the rate is genuinely 1 in 10,000, the label is doing the damage, not the number, and the argument has to be made against the label.

## What they said, and the interview line it rests on

> “Safety and the side-effect profile is the factor that carries the most weight for me. When I'm deciding between treatment options, safety is probably the most important, and evidence that it works—the efficacy—is the next most important for me to choose. Obviously, I have to make sure it's the right medication for the patient based on clinical evidence. While I will say that what the patient's insurance will actually approve ultimately dictates what they get—insurance is a major roadblock—when it comes to my clinical decision of what to choose, safety comes first. I definitely don't base it on what the patient asks for; I don't prescribe stuff just because patients want it, and if they demand something inappropriate, I let them leave my practice.”
>
> *Predicted from this line in the interview:* “Safety is probably the most important, and evidence that it works is the next most important for me to choose.”
>
> — Dermatologist in a large group practice, 5 to 15 years out of residency, starts several patients a month on systemic therapy · supports f1

> “I would say often, roughly half of starts. Dealing with insurance is probably the most frustrating part of my job, and it occupies about 30% of my time now. I frequently find myself in situations where I write a prescription for my first choice, and then the insurance comes back and says it's not covered, meaning the patient has to go on a different medication. I've definitely written for one systemic agent, had it denied, and just said, 'okay, sure, I'll switch it' to whatever is covered because it's not worth the endless appeals, especially when my medical assistant is getting denied for biologics 10 times in a row.”
>
> *Predicted from this line in the interview:* “it comes down to either patient insurance, you know, I've definitely written for one, and then the insurance says, no, that one's not covered, they have to go on the other. And I just say, okay, sure, I'll switch it.”
>
> — Dermatologist in a solo or small private practice, 16 to 25 years out of residency, starts several patients a month on systemic therapy · supports f2

> “I would explain the differences between the two agents to the patient and let them decide. Even on a first visit for systemic therapy, I always present all available options. I would go over the fact that Agent A is more efficacious and has a better safety profile, but costs $75 more per month out of pocket. Then I'd explain that Agent B is an older option that would save them some money, but it requires more lab monitoring and carries a higher risk of side effects. I think patients should have all the information and base their decision on their own comfort level with the risk-benefit ratio and the financial cost.”
>
> *Predicted from this line in the interview:* “inevitably I will get the question, well, how expensive is this medication? And so we go through that process and, and then based on those, then we decide whether or not we want to move forward with it.”
>
> — Dermatologist in a solo or small private practice, 5 to 15 years out of residency, starts several patients a month on systemic therapy · supports f3

> “For me, the biggest hurdle to using a new systemic agent as a first-line option is usually insurance mandates. I don't believe in making a patient suffer through months of a topical that's clearly not working just to tick a box, but insurers often want documentation that you've tried and failed those older first-line therapies before they'll cover a biologic or JAK inhibitor. If a new systemic had formulary coverage without step-therapy requirements, it would remove that massive bureaucratic barrier and allow me to treat the patient in front of me based on their actual needs rather than a rigid algorithm. Access is everything; if a drug isn't covered, it might as well not exist.”
>
> *Predicted from this line in the interview:* “I think the only thing I'd emphasise is access. We have all these amazing new treatments... but if patients can't access them because of cost or insurance barriers, they might as well not exist.”
>
> — Dermatologist in a large group practice, 5 to 15 years out of residency, starts several patients a month on systemic therapy · supports f4

## How much should you trust this?

**What we would defend**

- That safety, not cost, is what US dermatologists say carries the most weight when they choose a systemic agent: 40.9% name it (n=127), it is the top or joint-top answer in every practice setting and experience band of 30 or more except solo and small practices, where efficacy leads by one respondent (14 to 13 of 38), and out-of-pocket cost is named by 3 of 127.
- That coverage and cost override that stated order in practice: 46.9% say it happened in about half of their starts or more over the last year and 89.8% at least roughly one start in five (n=128); 43% say their most recent start was not the agent they would have chosen on clinical grounds, 39.1% because the first choice was denied or not covered (n=128). Over a third in every segment of 30 or more, highest at academic medical centers (26 of 38).
- The slope of the cost curve: prescribing the preferred agent outright falls from 69.3% to 12.6% at $75 more a month and 1.6% at $300 (n=127), monotonically in every segment of 30 or more and for every one of the 127 respondents individually; nobody chose the older agent outright at any level; and each series' reasoning named its own figure (118 of 127 at $75, 124 of 127 at $300, never the other).
- That formulary access without step therapy is the single thing most likely to move a new agent to first line (39.4%, n=127), ahead of five years of safety data (33.1%) and a head-to-head superiority trial (22.8%), and that the answer tracks each dermatologist's own constraint: 55.6% of those whose last start was overridden pick formulary access (n=54), 61.5% of those who weigh safety first pick five years of safety data (n=52) and 42.9% of those who weigh efficacy first pick the head-to-head trial (n=42).

**What we would not**

- Any sensitivity to the size of a rare risk. Offered a clearly more effective agent carrying a boxed warning, 89.7% would use it only after their current first choice had failed at about 1 in 1,000 patients a year (n=126) and 89.0% at about 1 in 10,000 (n=127); 115 of 126 gave the same answer at both rates, and only 16 and 10 reasonings mention the rate at all. The panel answered the boxed warning, not the number; the direction, that a boxed warning demotes a more effective agent to second line, is all we would stand behind.
- "Let the patient decide" as a prescription of the cheaper agent. At $75 and $300 the panel hands the choice to the patient; what the patient then chooses was not asked. The 87.4% is a change in who decides, not a share of prescriptions.
- The 78.0% who would let the patient decide in the three-week prior-authorization scenario as a reaction to the delay (n=127): 30 of 127 reasonings mention the three weeks and 105 answer as shared decision-making in general. The access matrix Ask Brox added is the better read of delay, and it is the one on the page.
- The 95.3% who use a biosimilar only when the payer requires it as anything more than direction (n=127): it is near-unanimous and nothing was asked about which biologic or which biosimilar.
- Anything about the 11 hospital-employed dermatologists, the 20 with 16 to 25 years in practice, the 7 with more than 25, the 24 who weigh coverage first or the 22 identifiable residents, beyond the counts stated.
- The 2.4% naming out-of-pocket cost as the top factor as evidence that cost does not matter: the same panel scores cost at 8 or more out of 10 for changing which agent they prescribe (82.7%, n=127). Cost is not what they weigh first; it is what changes the answer.

**The main limitation:** Stated intent from clones of 127 US dermatologists who prescribe systemic therapy, not observed prescribing or claims. The panel is early-career: 54 of 128 have been out of residency fewer than five years, and 22 describe themselves as residents still in training; without those 22 the headline figures barely move (safety first 39.0%, coverage override in about half of starts or more 42.9%, preferred agent outright 72.4% at no extra cost and 13.3% at $75, n=105). The panel carries no gender, age or state data, practice settings are evenly split (38 each in solo or small, large group and academic), the scenarios were anchored on plaque psoriasis, and every split is one of the study's own questions joined by respondent.

## How was this run?

| Segment | Clones |
|---|---:|
| Solo or small private practice | 38 |
| Large single-specialty or multi-specialty group practice | 38 |
| Academic medical center | 38 |
| Hospital-employed or integrated health system | 11 |
| Other setting | 2 |

**Question wording as fielded**

1. How often do you start patients on a systemic therapy (a biologic, an oral JAK inhibitor or a conventional oral systemic) for an inflammatory skin disease?
2. Which one best describes your main practice setting?
3. How many years have you been in practice since completing residency?
4. When you choose which systemic agent to start for a patient with moderate-to-severe inflammatory skin disease, which ONE of the following carries the most weight in your decision?
5. Think about the last patient you started on a systemic therapy. Was the agent you prescribed the one you would have chosen on clinical grounds alone?
6. Over the last 12 months, how often has insurance coverage or patient cost led you to start a systemic agent that was not your clinical first choice?
7. A 45-year-old patient with moderate-to-severe plaque psoriasis and no relevant comorbidities has not responded adequately to topical therapy and phototherapy. Agent A is the systemic therapy you would normally choose first: a newer agent with the strongest efficacy and safety data in your experience. Agent B is an older systemic therapy that you consider adequately effective but that needs more laboratory monitoring and has a less favorable side-effect profile. Both are covered by the patient's insurance. Which would you prescribe? [series: Agent A would cost the patient nothing more per month out of pocket than Agent B]
8. A 45-year-old patient with moderate-to-severe plaque psoriasis and no relevant comorbidities has not responded adequately to topical therapy and phototherapy. Agent A is the systemic therapy you would normally choose first: a newer agent with the strongest efficacy and safety data in your experience. Agent B is an older systemic therapy that you consider adequately effective but that needs more laboratory monitoring and has a less favorable side-effect profile. Both are covered by the patient's insurance. Which would you prescribe? [series: Agent A would cost the patient $75 more per month out of pocket than Agent B]
9. A 45-year-old patient with moderate-to-severe plaque psoriasis and no relevant comorbidities has not responded adequately to topical therapy and phototherapy. Agent A is the systemic therapy you would normally choose first: a newer agent with the strongest efficacy and safety data in your experience. Agent B is an older systemic therapy that you consider adequately effective but that needs more laboratory monitoring and has a less favorable side-effect profile. Both are covered by the patient's insurance. Which would you prescribe? [series: Agent A would cost the patient $300 more per month out of pocket than Agent B]
10. A 45-year-old patient with moderate-to-severe plaque psoriasis and no relevant comorbidities has not responded adequately to topical therapy and phototherapy. Your preferred systemic agent requires a prior authorization that your office expects to take about three weeks and that is sometimes denied. A different agent, which you consider somewhat less effective but clinically acceptable, is on the patient's formulary and could be started this week. What would you do?
11. A new systemic therapy for moderate-to-severe plaque psoriasis has shown clearly better efficacy than your current first-choice agent in a head-to-head trial. It carries a boxed warning for a rare serious adverse event, and your current first-choice agent does not carry that warning. Cost, insurance coverage, dosing and monitoring are otherwise the same. Would you make the new agent your first choice for a typical patient? [series: Rare serious adverse event estimated at about 1 in 1,000 patients per year]
12. A new systemic therapy for moderate-to-severe plaque psoriasis has shown clearly better efficacy than your current first-choice agent in a head-to-head trial. It carries a boxed warning for a rare serious adverse event, and your current first-choice agent does not carry that warning. Cost, insurance coverage, dosing and monitoring are otherwise the same. Would you make the new agent your first choice for a typical patient? [series: Rare serious adverse event estimated at about 1 in 10,000 patients per year]
13. On a scale of 0 to 10, how much does a patient's likely out-of-pocket cost change which systemic agent you prescribe, where 0 means it never changes my choice and 10 means it decides my choice?
14. Which ONE of the following would most increase your willingness to prescribe a new systemic agent as a first-line option?
15. When a lower-cost biosimilar of a biologic you prescribe becomes available, what do you typically do?
16. When you start systemic treatment for inflammatory skin disease, which treatment goals are you most trying to achieve for the patient at that moment?
17. What specific safety concerns are most likely to make you rule out or avoid a systemic therapy, even when efficacy looks strong?
18. When insurance coverage or patient cost prevents you from using your preferred systemic agent, what do you usually do next?
19. Which access barriers most often interfere with getting a patient started on the systemic therapy you think is most appropriate?
20. If your preferred systemic therapy for inflammatory skin disease were expected to face each of the following access situations, how likely would you be to stay with that therapy rather than switch to another acceptable option? Where the situation is [series: Prior authorization expected to take about 1 week]
21. If your preferred systemic therapy for inflammatory skin disease were expected to face each of the following access situations, how likely would you be to stay with that therapy rather than switch to another acceptable option? Where the situation is [series: Prior authorization expected to take about 3 weeks]
22. If your preferred systemic therapy for inflammatory skin disease were expected to face each of the following access situations, how likely would you be to stay with that therapy rather than switch to another acceptable option? Where the situation is [series: Step therapy requiring one lower-cost systemic first]
23. If your preferred systemic therapy for inflammatory skin disease were expected to face each of the following access situations, how likely would you be to stay with that therapy rather than switch to another acceptable option? Where the situation is [series: Expected patient out-of-pocket cost higher than alternatives but still manageable]
24. If your preferred systemic therapy for inflammatory skin disease were expected to face each of the following access situations, how likely would you be to stay with that therapy rather than switch to another acceptable option? Where the situation is [series: Uncertain coverage outcome at the time of prescribing]
25. For which of the following situations would you be most open to using a biosimilar in inflammatory skin disease?
26. What would you need to feel confident using a biosimilar more often in your systemic dermatology practice?

**What was not asked, and why:** No drug, brand, biosimilar or pharmaceutical company was named in any question or option, and the study asked Ask Brox not to add any; none appeared. The scenarios were anchored on plaque psoriasis in a 45-year-old with no comorbidities; atopic dermatitis, hidradenitis and pediatric prescribing were not tested. Respondents were not asked which agents they prescribe, what share of their patients are on a systemic, or their payer mix, so "coverage" is whatever their own patient panels look like, and what a patient chooses once handed the decision was not asked. Ask Brox added seven questions of its own (treatment goals, disqualifying safety concerns, what they do next when coverage blocks the preferred agent, the access barriers they meet, a five-situation access matrix, when they would use a biosimilar, and what would make them confident using one); three are quoted as context and all are in the data table.

## About this finding

The figures are predicted responses from 127 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US dermatologists (US), fielded on 2026-09-14 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox HCP Dermatologists panel, US, 127 clones of practicing dermatologists who prescribe systemic therapy (128 screened, none rejected); long-form video interviews with the 127 real dermatologists the clones are built from.
External: [Cost Consciousness Among Dermatologists (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745169/), [Administrative Burden and Costs of Prior Authorizations in a Dermatology Department (PubMed)](https://pubmed.ncbi.nlm.nih.gov/32845288/).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice.csv), [JSON](https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice.json). Page: https://reports.brox.ai/insights/dermatologists-put-safety-first-but-coverage-overrides-systemic-choice

---

Ask this of your own customers: humans@brox.ai
